Loading...
•
Sep 30, 2022
10X Genomics Q3 2022 Earnings Report
Reported a 5% increase in revenue compared to the corresponding period of 2021 and a 14% increase over second quarter of 2022.
Key Takeaways
10x Genomics reported revenue of $131.1 million for the third quarter of 2022, representing a 5% increase compared to the same period in 2021. The increase was primarily driven by higher volume of units sold and growth due to new customers, partially offset by unfavorable foreign exchange fluctuations. The company is maintaining its full year 2022 revenue guidance of $500 million to $520 million.
Revenue was $131.1 million for the third quarter, representing a 5% increase over the corresponding period of 2021 and a 14% increase over second quarter of 2022.
Published a preprint highlighting the power of the company's combined technologies – Chromium, Visium and Xenium – to draw important and previously inaccessible insights from human breast cancer FFPE tissue.
Released Xenium data and a preview of Xenium Explorer, the company's intuitive analysis and interactive visualization tool, reflecting the company's long-standing leadership and software expertise.
Demonstrated compatibility with two long-read sequencing partners to open up powerful new single cell and spatial applications using full-length transcripts.
Forward Guidance
10x Genomics is maintaining its previously announced full year 2022 revenue guidance of $500 million to $520 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...